EcoDrugPlus

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSAPOG00000011120
Gene Symbol: HTR4
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSAPOG00000011758
Gene Symbol: HTR5A
3 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSAPOG00000015346
Gene Symbol: HTR6
3 Cross references
115 Possible Orthologues:

60s Ribosomal Protein L18-Like

Ensembl ID : ENSAPOG00000009568
Gene Symbol: LOC110946125
3 Cross references
377 Possible Orthologues:

60s Ribosomal Protein L18-Like

Ensembl ID : ENSAPOG00000021617
Gene Symbol: LOC110972467
3 Cross references
377 Possible Orthologues:

60s Ribosomal Protein L19-Like

Ensembl ID : ENSAPOG00000020065
Gene Symbol: LOC110949579
4 Cross references
331 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSAPOG00000022940
Gene Symbol: LOC110971657
3 Cross references
383 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSAPOG00000006788
Gene Symbol: LOC110956348
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L3

Ensembl ID : ENSAPOG00000019827
Gene Symbol: LOC110951548
3 Cross references
337 Possible Orthologues:

60s Ribosomal Protein L3-Like

Ensembl ID : ENSAPOG00000011893
Gene Symbol: LOC110947022
3 Cross references
337 Possible Orthologues:

60s Ribosomal Protein L35a-Like

Ensembl ID : ENSAPOG00000009023
Gene Symbol: LOC110947428
3 Cross references
510 Possible Orthologues:

60s Ribosomal Protein L35a-Like

Ensembl ID : ENSAPOG00000006598
Gene Symbol: LOC110947536
3 Cross references
510 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).